EP300, a crucial target of glycosides, impacts viral myocarditis, chemotaxis of monocytes and macrophages, and T-cell activation, leading to antibody responses, potentially serving as a therapeutic target for influenza A viruses (64). The gene discussed is EP300; the disease is viral myocarditis.